The majority of materials we rely on in our built environment come from chemicals derived from petroleum (petrochemicals), ...

IMUNON (IMNN) announced the presentation of new clinical data from the recently completed Phase 2 OVATION 2 Study of IMNN-001, its ...

Finally, the researchers describe a way to exploit ecDNA’s high rate of replication and transcription: a conflict between DNA ...

The ability to genetically engineer plants is largely thanks to a microscopic helper: a bacterium called Agrobacterium ...

Adapted from a news release by the Innovative Genomics Institute (IGI) at UC Berkeley.The ability to genetically engineer plants is largely thanks to ...

As previously announced, IMUNON plans to hold an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) in person to discuss the design for a Phase 3 pivotal study of IMNN-001 in ...

Research and development expenses were $9.4 million for the nine months ended September 30, 2024, compared with $7.7 million for the nine months ended September 30, 2023. General and administrative ...

PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, has presented new data on its lead ...

PulseSight plans to submit a phase I clinical trial authorization (CTA) by the end the year, to be closely followed by a phase II proof-of-concept to demonstrate the efficacy and the safety of its ...

This novel DNA plasmid vaccine targets antigen-presenting cells and aims to induce a robust immune response. Prof. Lindy ...